San Diego, United States
Crown Bioscience is a prominent player in the Biotechnology and Pharmaceutical industries, operating as a global contract research organization. Founded in 2006, it has positioned itself as a leader in accelerating drug discovery and development, particularly in oncology and immuno-oncology.
Leveraging innovative and tailored solutions, the company provides extensive preclinical research and clinical trial support. A standout feature is its vast collection of patient-derived xenograft (PDX) models, contributing valuable insights into 35 cancer indications. The company's robust expertise across in vivo, in vitro, ex vivo, and in silico methods enhances its comprehensive service offerings.
Crown Bioscience's facilities—strategically located across US, Europe, and APAC—are state-of-the-art, meeting CAP and ISO accreditations. The company's recent $204M acquisition by Adicon Holdings on 01 November 2025 underscores its financial strength and strategic appeal in the life sciences sector.
